HANSOH PHARMA (03692) released its annual performance with a net profit attributable to shareholders of 5.55 billion yuan, an increase of 27.07% year-on-year.

HANSOH PHARMA (03692) announced its financial results for the year ending December 31, 2025. The group achieved a revenue of RMB 15.028 billion, representing a year-on-year growth of 22.57%. The attributable net profit to the owners of the parent company was RMB 5.555 billion, an increase of 27.07% compared to the previous year. The basic earnings per share was RMB 0.93. The company plans to distribute a final dividend of HK$0.20 per share. According to the announcement, the company is a leading innovative pharmaceutical enterprise in China, with a mission of "continuous innovation, improving human life quality". It focuses on major disease treatment areas such as anti-tumor, anti-infection, central nervous system (CNS), metabolism, and autoimmune diseases. The company has seven innovative drugs that generate sales revenue in China, forming a rich product pipeline. As of the year ending December 31, 2025, the sales revenue from innovative drugs and collaboration products was approximately RMB 12.354 billion, accounting for about 82.2% of the total revenue, and has become the core driver of sustainable performance growth for the group. The company's revenue mainly comes from the sales of pharmaceutical products. Its main products are concentrated in the key treatment areas that the group strategically focuses on, including anti-tumor, anti-infection, CNS, metabolism, and other diseases. The increase in revenue, net profit for the year, and basic earnings per share during the reporting period were mainly due to the increase in sales revenue from innovative drugs and collaboration products.